Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim's Pradaxa has set the bar by showing superiority to standard-of-care warfarin, and Daiichi Sankyo has staked a lot on an ongoing Phase III comparison study of Lixiana (edoxaban) to warfarin for the prevention of thromboembolism in atrial fibrillation, expected to report in 2012.